Medical and Regulatory Affairs

Medical and Regulatory Affairs

What’s New in Regulations? Premier Research Chairing 2 Sessions at DIA 2015

Experts from Premier Research will examine how regulatory changes are affecting clinical trials and medical device makers when they chair two sessions at the DIA 2015 51st Annual Meeting, June 14-18 in Washington, DC.

Medical and Regulatory Affairs

Regulation of Orphan Drugs: May 19 Webinar Offers Important Insights

Join Nach Dave and Carol Huntington of Premier Research for Orphan Drug & Rare Disease Development: Understanding the European and US Regulatory Landscape. The hour-long event, beginning at 11am EDT, 4pm BST, and 5pm CEST, is aimed at researchers and pharma companies tackling some of the 7,000 rare diseases identified by the National Institutes of Health.

Medical and Regulatory Affairs

Premier Research Expands Certification Under ISO Standard for Medical Device and Diagnostics

On Monday, June 30, 2014, Premier Research expanded its ISO certification as a provider of strategic and regulatory consulting, clinical development, and post-marketing surveillance services to manufacturers of medical devices and diagnostics. This certification includes ISO 9001:2008 and aspects of ISO 13485:2003, the key quality management standards required by international regulatory authorities and—therefore—by Premier’s customers.

Medical and Regulatory Affairs

Premier Research to Present at the 24th Annual EuroDIA Meeting

Sherri Hubby, Director, US Quality Assurance, will present “A Global Perspective from Ethics, Accreditation Bodies and Industry on Conducting Clinical Trials to Ensure Compliance” on Tuesday, March 27 at 16:00. With the increased challenges that come with conducting clinical trials in global markets and shortened timelines, many groups must work together to achieve balance and build public assurance. This session will review how quality programs are being conducted to assess compliance and to ensure consistency of ethical review and decision-making despite cultural differences. Practical information will be shared including how to identify gaps for managing clinical trial weaknesses and audit readiness tips.

Data Management & Biostatistics

Premier Research Announces Adoption of eTMF System

Premier Research announced today that it will use a new electronic Trial Master File (eTMF) system on all Clinical Development Services Studies. Trial Interactive has been tapped to provide the supporting platform. The adoption of eTMF is the company’s latest investment in its 2012-2013 technology RoadMap focused on three key areas ...

Medical and Regulatory Affairs

Premier Research’s New Analgesia Survey Reveals Confusion around ePRO Regulatory Guidance

A new survey of analgesia clinical trial decision makers commissioned by Premier Research and involving 51 pharmaceutical and biotech firms primarily in North America and Europe reveals that while three out of four respondents (75%) have some recent experience with the use of ePRO (electronic patient-reported outcomes) technologies in clinical trials, about the same number (76%) are confused or even unfamiliar with the regulatory guidance for the use of the technology.

Medical and Regulatory Affairs

Premier Research Survey Finds Many Sponsors Ignore Pediatric Requirements for Clinical Trials

The Pediatric Research Equity Act (PREA)—requiring drug makers to test all drugs for safety and efficacy in pediatric populations as well as in adults—was passed in 2003 and updated in 2007. And in Europe, a similar requirement has been in effect since 2007.

Medical and Regulatory Affairs

New Survey Reveals Companies’ Concerns About Too Few Pediatric Patients for Clinical Trials Premier Research’s Survey Also Reveals Confusion About PREA and Its EU Counterpart

A new biopharma survey of 55 biotech and pharmaceutical firms in both the North America and European markets by Premier Research reveals that the biggest problem those companies are facing in complying with pediatric regulations is that there may not be enough children who are both accessible and can meet often stringent study criteria to participate in the required clinical trials.